| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/15/2011 | CA2496708C New process for the synthesis of (1s)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and its addition salts and application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid |
| 03/15/2011 | CA2490571C Pyrazoloisoquinoline derivatives for inhibiting nfkappab-inducing kinase (nik) |
| 03/15/2011 | CA2480708C Method and dietary composition for improving fat digestibility |
| 03/15/2011 | CA2477774C Indolylmaleimide derivatives |
| 03/15/2011 | CA2474262C Short-acting sedative hypnotic agents for anesthesia and sedation |
| 03/15/2011 | CA2473910C Pyrimidine derivatives as rho-kinase inhibitors |
| 03/15/2011 | CA2473232C Histamine-3 receptor ligands for diabetic conditions |
| 03/15/2011 | CA2473160C Composition for pharmaceutical or dietetic use for combating hair loss |
| 03/15/2011 | CA2472586C Use of polysaccharide derivatives as antiinfective substances |
| 03/15/2011 | CA2471814C Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient |
| 03/15/2011 | CA2470703C Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 03/15/2011 | CA2470583C Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| 03/15/2011 | CA2470423C Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 03/15/2011 | CA2469788C Method for preparing a glucosamine compound, and compound thus obtained |
| 03/15/2011 | CA2468311C Benzothiazole derivatives |
| 03/15/2011 | CA2463681C Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 03/15/2011 | CA2462228C 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents |
| 03/15/2011 | CA2458318C Wortmannin analogs and methods of using same |
| 03/15/2011 | CA2458266C Substituted urea retinoid agonists ii |
| 03/15/2011 | CA2451230C Eurotinones, and derivatives thereof, processes for preparing them, and their use |
| 03/15/2011 | CA2450820C Processes for preparing calcium salt forms of statins |
| 03/15/2011 | CA2443235C Pharmaceutical compositions comprising ascomycin |
| 03/15/2011 | CA2438426C Calcium supplementation to reduce prostate cancer risk |
| 03/15/2011 | CA2434169C Spaced drug delivery system |
| 03/15/2011 | CA2432000C Pyrimidineamines as angiogenesis modulators |
| 03/15/2011 | CA2431160C Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 03/15/2011 | CA2430332C Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of urinary incontinence |
| 03/15/2011 | CA2429935C Compositions and methods for treating hyperpigmentation |
| 03/15/2011 | CA2429526C Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine |
| 03/15/2011 | CA2426974C Coated medical devices |
| 03/15/2011 | CA2426921C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 03/15/2011 | CA2426440C Quinazoline derivatives as kinase inhibitors |
| 03/15/2011 | CA2423568C Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
| 03/15/2011 | CA2422375C 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| 03/15/2011 | CA2415611C Biologically active macrolides, compositions, and uses thereof |
| 03/15/2011 | CA2412776C Compositions controlling release ph range and/or speed |
| 03/15/2011 | CA2406064C Minimizing adverse experience associated with oxybutynin therapy |
| 03/15/2011 | CA2406008C Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 03/15/2011 | CA2404196C Medical emulsion for lubrication and delivery of drugs |
| 03/15/2011 | CA2402038C Lpa receptor agonists and antagonists and methods of use |
| 03/15/2011 | CA2397681C Partially saturated calcium channel blockers |
| 03/15/2011 | CA2397366C Methanocarba cycloalkyl nucleoside analogues |
| 03/15/2011 | CA2396030C Camptothecin .beta.-alanine esters with topoisomerase i inhibition |
| 03/15/2011 | CA2394809C Benzazole derivatives and their use as jnk modulators |
| 03/15/2011 | CA2383284C Use of ribose to prevent cramping and soreness in muscles |
| 03/15/2011 | CA2379575C Pharmaceutically active sulfonamide derivatives |
| 03/15/2011 | CA2376326C Unfermented gel fraction from psyllium seed husks |
| 03/15/2011 | CA2376158C Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain |
| 03/15/2011 | CA2373653C New use of compounds as antibacterial agents |
| 03/15/2011 | CA2360415C Benzimidazole vascular damaging agents |
| 03/15/2011 | CA2343009C Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| 03/15/2011 | CA2338982C Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
| 03/15/2011 | CA2315117C Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission |
| 03/15/2011 | CA2289119C Methods for treating inflammation and inflammatory diseases using padprt inhibitors |
| 03/15/2011 | CA2232191C Inhibition of tumor necrosis factor alpha |
| 03/10/2011 | WO2011029099A1 Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity |
| 03/10/2011 | WO2011029088A2 Preparation of raloxifene and its salts |
| 03/10/2011 | WO2011029059A1 Use of aerosolized levofloxacin for treating cystic fibrosis |
| 03/10/2011 | WO2011029054A1 Compositions and methods for treatment of leukemia |
| 03/10/2011 | WO2011029027A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| 03/10/2011 | WO2011029005A1 Crystalline forms of fesoterodine fumarate and fesoterodine base |
| 03/10/2011 | WO2011029001A1 Compounds as tyrosine kinase modulators |
| 03/10/2011 | WO2011028995A1 Compounds as tyrosine kinase modulators |
| 03/10/2011 | WO2011028947A2 Heterocyclic compounds for the inhibition of pask |
| 03/10/2011 | WO2011028941A2 Disabling autophagy as a treatment for lysosomal storage diseases |
| 03/10/2011 | WO2011028938A1 Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| 03/10/2011 | WO2011028935A2 Methods of treating mitochondrial disorders using metalloporhyrins |
| 03/10/2011 | WO2011028927A1 Selective sphingosine-1-phosphate receptor antagonists |
| 03/10/2011 | WO2011028922A1 Substituted xanthine derivatives |
| 03/10/2011 | WO2011028864A1 Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
| 03/10/2011 | WO2011028860A2 Compounds and compositions for treating cancer |
| 03/10/2011 | WO2011028835A1 Substituted xanthine derivatives |
| 03/10/2011 | WO2011028813A2 Insulin analogues of enhanced receptor-binding specificity |
| 03/10/2011 | WO2011028800A2 Treatment of cognitive dysfunction with gangliosides |
| 03/10/2011 | WO2011028799A2 Ganglioside transmucosal formulations |
| 03/10/2011 | WO2011028797A2 Treatment of glaucoma and other retinopathies with gangliosides |
| 03/10/2011 | WO2011028794A2 Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| 03/10/2011 | WO2011028779A1 Iminosugars and methods of treating filoviral diseases |
| 03/10/2011 | WO2011028743A1 Pharmaceutical formulations for indibulin |
| 03/10/2011 | WO2011028741A1 Quinazolines as potassium ion channel inhibitors |
| 03/10/2011 | WO2011028740A1 ENaC BLOCKERS |
| 03/10/2011 | WO2011028737A2 Bisphosphonate compositions and methods for treating heart failure |
| 03/10/2011 | WO2011028718A1 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 03/10/2011 | WO2011028689A1 Fatty acid niacin conjugates and their uses |
| 03/10/2011 | WO2011028685A1 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| 03/10/2011 | WO2011028654A1 Processes for isolation and purification of enfumafungin |
| 03/10/2011 | WO2011028651A1 Inhibitors of human 15-lipoxygenase-1 |
| 03/10/2011 | WO2011028638A1 Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 03/10/2011 | WO2011028629A1 Pharmaceutical formulations and methods of use |
| 03/10/2011 | WO2011028621A1 Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
| 03/10/2011 | WO2011028611A1 P2x7: inhibition of epithelial cancers and papillomas |
| 03/10/2011 | WO2011028594A2 Cancer starvation therapy |
| 03/10/2011 | WO2011028580A1 Novel forms of a multicyclic compound |
| 03/10/2011 | WO2011028548A1 Synthesis of a neurostimulative piperazine |
| 03/10/2011 | WO2011028542A2 Methods of treating pain associated with complex regional pain syndrome |
| 03/10/2011 | WO2011028503A1 Methods for treating acute acoustic trauma |
| 03/10/2011 | WO2011028495A1 Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof |
| 03/10/2011 | WO2011028492A2 Sortase a inhibitors |
| 03/10/2011 | WO2011028455A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 03/10/2011 | WO2011028418A1 An automated method and system for the analysis of total dietary fiber |